Inventor
Gerold L. Mosher
Inventor
Kansas City, MO, US
Overview
Patents· 50 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
A61Kprimary
A61KPreparations for medical, dental or toiletry purposes32%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations20%
B82YSpecific uses or applications of nanostructures11%
C08BPolysaccharides10%
C08LCompositions of macromolecular compounds7%
Y10TTechnical subjects covered by former us classification7%
B01DSeparation5%
B01JChemical or physical processes, e.g. catalysis or colloid chemistry4%
C07HSugars4%
C07DHeterocyclic compounds1%
PatentTitleYear
11,040,023Enalapril formulations202110,959,991Amlodipine formulations202110,952,998Amlodipine formulations202110,940,177Lisinopril formulations202110,918,621Enalapril formulations202110,894,039Amlodipine formulations202110,799,453Amlodipine formulations202010,799,599Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid202010,799,476Enalapril formulations202010,786,482Enalapril formulations202010,772,868Enalapril formulations202010,703,826Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof202010,695,329Amlodipine formulations202010,668,160DPI formulation containing sulfoalkyl ether cyclodextrin202010,512,697Formulations containing clopidogrel and sulfoalkyl ether cyclodextrin and methods of use201910,406,199Lisinopril formulations201910,265,370Lisinopril formulations201910,207,008Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid201910,202,468Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof201910,159,752Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid201810,154,987Enalapril formulations201810,117,940DPI formulation containing sulfoalkyl ether cyclodextrin201810,111,863Pharmaceutical compositions comprising prasugrel and cyclodextrin derivatives and methods of making and using the same201810,039,745Enalapril formulations201810,039,800Lisinopril formulations201810,034,947Formulations containing clopidogrel and sulfoalkyl ether cyclodextrin and methods of use20189,827,324Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid20179,814,751'Lisinopril formulations'20179,808,442'Enalapril formulations'20179,669,008'Enalapril formulations'20179,623,045'Formulations containing clopidogrel and sulfoalkyl ether cyclodextrin and methods of use'20179,617,352'Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof'20179,616,096'Lisinopril formulations'20179,463,183'Lisinopril formulations'20169,399,067'Pharmaceutical compositions comprising prasugrel and cyclodextrin derivatives and methods of making and using the same'20169,125,945'Formulations containing clopidogrel and sulfoalkyl ether cyclodextrin and methods of use'20158,853,236'Formulations containing clopidogrel and sulfoalkyl ether cyclodextrin and methods of use'20148,846,901'Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof'20148,835,407'Pharmaceutical compositions comprising prasugrel and cyclodextrin derivatives and methods of making and using the same'20148,829,182'Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof'20148,343,995'Formulations containing clopidogrel and sulfoalkyl ether cyclodextrin and methods of use'20138,236,782'Pharmaceutical compositions comprising prasugrel and cyclodextrin derivatives and methods of making and using the same'20128,114,438'DPI formulation containing sulfoalkyl ether cyclodextrin'20128,049,003'Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof'20117,629,331'Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof'20097,034,013'Formulations containing propofol and a sulfoalkyl ether cyclodextrin'20066,869,939'Formulations containing amiodarone and sulfoalkyl ether cyclodextrin'20056,046,177'Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations'20005,525,596'Absorption enhancer/solubilizer combination for improved bioavailability of a zwitterionic compound'19965,063,224'R-cefuroxime axetil'1991Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
1991Based in Indianapolis, IN, US· patent location history
1996Based in Lawrence, KS, US· patent location history
2000–2021Based in Kansas City, MO, US· patent location history
2009–2020Patents assigned to CYDEX PHARMACEUTICALS INC (24)· patent assignee history
2012–2020Patents assigned to MOSHER GEROLD L (7)· patent assignee history
2012–2020Patents assigned to PIPKIN JAMES D (4)· patent assignee history
2012–2014Patents assigned to CUSHING DANIEL J (3)· patent assignee history
2016–2021Patents assigned to SILVERGATE PHARMACEUTICALS INC (21)· patent assignee history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| CYDEX PHARMACEUTICALS INC | 24 | 2009–2020 |
| SILVERGATE PHARMACEUTICALS INC | 21 | 2016–2021 |
| MOSHER GEROLD Lself | 7 | 2012–2020 |
| PIPKIN JAMES D | 4 | 2012–2020 |
| CUSHING DANIEL J | 3 | 2012–2014 |
Locations
| Location | Patents | Span |
|---|---|---|
| Kansas City, MO, US | 48 | 2000–2021 |
| Lawrence, KS, US | 1 | 1996 |
| Indianapolis, IN, US | 1 | 1991 |